Ekso Bionics Announces EksoNR Multi-Unit Order by Nebraska Fraternal Order of Eagles

NEXT STORY
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
PREV STORY
HTG Expands Therapeutics Scientific Advisory Board With Addition of Dr. Jerald Radich
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Clinical Results for BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Demonstrated Superior Immune Profile Compared to Neulasta®

Company to Present Latest Findings at 2018 Society for Immunotherapy of Cancer’s (SITC) Annual ...

author_avatar
NASDAQ Market News

Neos Therapeutics Reports First Quarter 2018 Financial Results

Company to Host Conference Call at 8:30am ET TodayDALLAS and FORT WORTH, Texas, May ...

author_avatar
NASDAQ Market News

Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study

Target Exceeded with More than 160 Patients Enrolled Top-Line Data on Track for 3Q17 ...

author_avatar
NASDAQ Market News